Financial statements are reported in EUR. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
PRQR — ProQR Therapeutics N.V.
€1.28
+€0.05 (+3.68%)
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Market Cap
€180.70M
Forward P/E
-3.0x
52-Week Range
N/A
PRQR Price History
Revenue vs. Net Income
€18.9M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-€53.8M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-51.3%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
5.4%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+22.4%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
